Answered You can hire a professional tutor to get the answer.
Write 3 page essay on the topic A Journal Analysis: A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model.The long acting subcutaneous inject able
Write 3 page essay on the topic A Journal Analysis: A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model.
The long acting subcutaneous inject able agent can reduce the burden of care for the treatment of hemophilia A. The report of Kitazawa et al. (2012, p. 1570) is that 1 in every 10,000 males suffer from hemophilia A. Such people experience one bleeding episode every month with no preventive intervention. The patients with moderate hemophilia A have fewer bleeding episodes. Clinicians offer patients with severe hemophilia A routine prophylactic supplementation to keep the factors activity below 1 percent and reduce joint bleeds to promote quality life. Routine supplementation of FVIII other than its benefits has two main drawbacks: (1) it is expensive and it is a challenge to the impoverished in the society. (2) The development of inhibitors requires frequent access to FVIII injection. Inhibitors precluding the use of FVIII are difficult to control hemorrhage since alternative treatments depict short half-lives, are ineffective, and cost more than the VIII. The clinicians attempt eradicating inhibitors by use of high doses of FVIII while the process is expensive and ineffective. The need for frequent venous access is problematic especially when treating pediatric patients at home and it has a negative effect on the implementation and adherence to the supplementation routine. The use of a new agent will offer an alternative to the inherent drawbacks to the therapeutic use of FVIII to improve treatment possibilities for the patients with severe hemophilia A.
FVIII behave as a cofactor upon activation by thrombin or factor Xa. The resultant factor VIII consists of A1 subunit, light chain, and A2 subunit. The subunits bind with the light chain to contribute to the FVIII cofactor activity that can enhance catalytic rate of FIXa and the interaction of FIXa and FX.
The recombinant monoclonal antibodies have agonistic, antagonistic, catalytic, and allosteric activity to study therapeutic applications extensively. The bi specific
